The drug, called icotrokinra and developed together with Protagonist Therapeutics, is an oral peptide designed to tamp down ...
The agency turned back Astellas’ attempt to update its drug Izervay’s labeling. Elsewhere, former NCI director Ned Sharpless ...
The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback